Buccal Drug Delivery System Market Report 2025

The buccal drug delivery system market size has grown rapidly in recent years. It will grow from $3.55 billion in 2024 to $3.91 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to early drug delivery innovations, pharmaceutical industry adoption, clinical studies and efficacy, market penetration strategies, disease-specific applications.

The buccal drug delivery system market size is expected to see rapid growth in the next few years. It will grow to $5.97 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to patient-centric drug delivery, rising geriatric population, demand for targeted therapies, biologics and peptides delivery, regulatory support and approvals, investments in r&d. Major trends in the forecast period include patient convenience and compliance, advancements in drug formulations, rise in chronic diseases, pediatric and geriatric care, enhanced bioavailability.

The increasing prevalence of chronic diseases is anticipated to boost the growth of the buccal drug delivery systems market in the future. Chronic diseases are defined as health conditions that last for a year or more, including cancer, heart disease, stroke, diabetes, and arthritis. These illnesses are among the most common chronic conditions that can be managed but not cured, requiring ongoing medical care and nutrition. Buccal drug delivery systems offer an effective and suitable method for administering mucosal and transmucosal drugs needed by many patients suffering from chronic diseases such as diabetes and cancer. For instance, in September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths, accounting for 74% of global deaths caused by non-communicable diseases (NCDs) or chronic diseases, occur each year. Among these, there were 17.9 million deaths due to cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Thus, the increasing prevalence of chronic diseases is driving the growth of the buccal drug delivery systems market.

The rising demand in hospitals is expected to drive the growth of the buccal drug delivery systems market in the future. Hospitals are specialized facilities that provide medical treatment, care, and services to individuals who are ill or injured. In hospital settings, buccal drug delivery systems offer benefits such as rapid drug absorption, enhanced patient compliance, reduced gastrointestinal side effects, and controlled drug release. For example, in May 2023, a report from the American Hospital Association (AHA), a US-based healthcare trade organization representing hospitals and healthcare networks, indicated that the total number of hospitals increased to 6,129, up from 6,093 in 2022. Additionally, total admissions across all U.S. hospitals rose to 34,011,386, compared to 33,356,853 in 2022. Thus, the increasing demand in hospitals is propelling the growth of the buccal drug delivery systems market.

Leading companies in the buccal drug delivery systems market are concentrating on creating innovative solutions, such as oral treatments for plaque psoriasis, to enhance patient outcomes and improve drug delivery efficacy. Oral treatments for plaque psoriasis involve administering medications by mouth to manage and relieve the symptoms of this chronic autoimmune disorder, which is characterized by the rapid proliferation of skin cells resulting in thick, red, scaly patches. For example, in September 2022, Bristol Myers Squibb, a US-based pharmaceutical company, received FDA approval for Sotyktu (deucravacitinib), an oral treatment for adults suffering from moderate-to-severe plaque psoriasis. This approval represents the first new oral therapy for this condition in nearly a decade, introducing a novel mechanism of action as a selective inhibitor of tyrosine kinase 2 (TYK2).

Companies operating in the buccal drug delivery systems market are focusing on product launches to drive revenues. For instance, in February 2023, launch of melatonin oral spray by Arlak Biotech Private Limited. Melatonin oral spray provides an easy and effective way to facilitate the body's natural production of melatonin, aiding in improving sleep quality. This type of product launch addresses specific healthcare needs, contributing to the growth of the buccal drug delivery systems market.

In April 2023, DifGen Pharmaceuticals LLC, a US-based pharmaceutical company, acquired Aveva Drug Delivery Services Inc. This strategic acquisition aimed to enhance DifGen's research and development (R&D) and manufacturing capabilities, ensuring a secure supply of high-quality and cost-effective medications. Aveva Drug Delivery Services Inc. specializes in buccal drug delivery systems, aligning with DifGen's goal of providing advanced and reliable pharmaceutical solutions.

Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd., Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc., Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd., AstraZeneca PLC, F Hoffmann-La Roche Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Novo Nordisk A/S, Ethypharm SAS, Applied Pharma Research SA, Sunovion Pharmaceuticals Inc., Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc., NAPP Pharmaceutical Ltd., Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc., Par Pharmaceutical Companies Inc., Acorda Therapeutics Inc., Opiant Pharmaceuticals Inc.

North America was the largest region in the buccal drug delivery systems market share in 2024. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the buccal drug delivery system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The buccal drug delivery system involves administering the desired medicine through the buccal mucosal membrane lining of the mouth cavity. This method is effective for delivering mucosal and transmucosal drugs. Mucosal drug delivery aims for site-specific drug release on the mucosa, whereas transmucosal permeation entails drug absorption across the mucosal barrier and into the systemic circulation.

The main types of buccal drug delivery systems include sublingual, buccal tablets and lozenges, and oral sprays. The term sublingual refers to the route of administration for systemic medication delivery of buccal drugs. These are applied in various applications such as pain management, smoking cessation, and angina pectoris, and are utilized by hospitals, ambulatory care centers, and other healthcare facilities.

The buccal drug delivery system market research report is one of a series of new reports that provides buccal drug delivery system market statistics, including buccal drug delivery system industry global market size, regional shares, competitors with a buccal drug delivery system market share, detailed buccal drug delivery system market segments, market trends and opportunities, and any further data you may need to thrive in the buccal drug delivery system industry. This buccal drug delivery system market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The buccal drug delivery system market consists of the sales of drug ingredients such as insulin, nicotine, tizanidine, triptan, nifedipine, flurbiprofen, sodium carboxymethylcellulose, carbopol, glibenclamide, hyaluronic acid, and xanthan gum. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.